January 20, 2026

RENOVO | RX
INVESTOR RELATIONS

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- **RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT)**, a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company's **RenovoCath** patented FDA-cleared drug-delivery device into oncology treatment programs. The Company's **TAMP™ (Trans-Arterial Micro-Perfusion)** therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration.

The number of active commercial cancer centers which are eligible to order and use RenovoCath has increased from five in September 2025 to nine currently and growing with the addition of City of Hope Cancer Center in Duarte, California and Moffitt Cancer Center in Tampa, Florida. This positive development is strong evidence that RenovoRx's commercialization efforts for RenovoCath as a standalone device are taking hold in the market.

City of Hope Cancer Center's Chief of Interventional Radiology, Dr. Jonathan Kessler, was recently featured in an interview on Spectrum News 1 SoCal, highlighting how RenovoRx's patented TAMP therapy platform, enabled by RenovoCath, has the potential to reshape oncology management for patients diagnosed with difficult-to-treat tumors, like locally advanced pancreatic cancer. View the full interview at: https://ir.renovorx.com/news-events/clinical-news/detail/21002/new-device-delivers-targeted-chemo-for-pancreatic-cancer.

Moffitt Cancer Center also recently highlighted one pancreatic cancer patient's journey of receiving treatment with the TAMP therapy platform. View the full newsletter at: https://ir.renovorx.com/news-events/clinical-news/detail/20999/moffitt-using-new-approach-to-treat-pancreatic-cancer.

"The growing adoption of RenovoCath by esteemed institutions like City of Hope Cancer Center and Moffitt Cancer Center, amongst others, is the driver of our commercial efforts and underscores the clinical need for more targeted oncology tools," said Shaun Bagai, CEO of RenovoRx. "We are encouraged by both the procedural feedback and the strong commercial interest we are seeing."

Based on physician demand, in late 2024, RenovoRx made the decision to launch a small

effort to organically commercialize RenovoCath as a standalone device within its FDA cleared uses. In 2025, RenovoRx generated approximately $900,000 in sales revenue through September 2025.

Important lessons were learned in 2025 about customer approval processes, sales cycles, customer training, and insurance reimbursement. Encouraged by early results, RenovoRx strengthened its go-to-market strategy by establishing a small, but dedicated commercial team, including a new Senior Director of Sales and Market Development and a Director of Marketing, along with regional sales personnel, which was fully onboarded by the end of 2025. Since then, RenovoRx has seen accelerating adoption. By applying the lessons learned in 2025, RenovoRx is aiming for revenue growth in 2026, driven by increasing physician demand, effective procedural training initiatives, and heightened recognition of the differentiated value of RenovoCath's localized, targeted drug-delivery approach.

Importantly, the number of RenovoCath active customers does not include cancer centers that are currently participating in RenovoRx's ongoing Phase III TIGeR-PaC trial studying the Company's drug-device combination oncology product candidate, intra-arterial gemcitabine delivery via RenovoCath (known as IAG) for the treatment of locally advanced pancreatic cancer. Such centers could transition to commercial RenovoCath customers after full enrollment in the trial in the first half of this year.

For a full list of Cancer Centers and physicians offering treatment delivered by RenovoCath, visit: https://renovocath.com/.

About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). RenovoRx's first investigational drug-device combination product candidate, using the TAMP therapy platform enabled with the Company's FDA-cleared RenovoCath® device, is designed for the intra-arterial administration of chemotherapy, gemcitabine (IAG).

About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing **RenovoCath®**, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented **Trans-Arterial Micro-Perfusion (TAMP™)** therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of

diagnostic and therapeutic agents.

RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company's management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and our TAMP technology and the potential for revenue growth from such efforts. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results (including related to our revenues), which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as "may," "expects," "plans," "aims," "anticipates," "believes," "forecasts," "estimates," "intends," and "potential," or the negative of

these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate-;(v) that the applicable regulatory authorities may disagree with our interpretation of the data-, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRX@KCSA.com

Source: RenovoRx, Inc.